Aprotinin and tranexamic acid for high transfusion risk cardiac surgery

Annals of Thoracic Surgery

Volumn 69, Issue 3, 2000, Pages 808-816

  Wong, Bill I ^b   McLean, Richard F ^a   Fremes, Stephen E ^a   Deemar, Katherine A ^a   Harrington, Ellen M ^a   Christakis, George T ^a   Goldman, Bernard S ^a  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

APROTININ; HEMOGLOBIN; TRANEXAMIC ACID;

ADULT; AGED; AORTA ARCH; AORTA SURGERY; ARTICLE; BLOOD TRANSFUSION; CARDIOPULMONARY BYPASS; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG MEGADOSE; ELECTIVE SURGERY; HEART INFARCTION; HEART SURGERY; HEART VALVE SURGERY; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; OPERATION DURATION; POSTOPERATIVE HEMORRHAGE; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REGRESSION ANALYSIS; STERNOTOMY; STROKE; THORAX DRAINAGE;

ANTIFIBRINOLYTIC AGENTS; APROTININ; BLOOD TRANSFUSION; CARDIAC SURGICAL PROCEDURES; DOUBLE-BLIND METHOD; HEMOSTATICS; HUMANS; POSTOPERATIVE HEMORRHAGE; REGRESSION ANALYSIS; RISK FACTORS; TRANEXAMIC ACID;

EID: 0034108756     PISSN: 00034975     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0003-4975(99)01419-8     Document Type: Article

References (31)

1. Holloway D.S., Summaria L., Sandesara J., Vagher J.P., Alexander J.C., Caprini J.A. Decreased platelet number and function and increased fibrinolysis contribute to postoperative bleeding in cardiopulmonary bypass patients. Thromb Haemost. 59:1988;62-67.
2. Despotis G.J., Filos K.S., Zoys T.N., Hogue C.W., Spitznagel E., Lappas D.G. Factors associated with excessive postoperative blood loss and hemostatic transfusion requirements a multivariate analysis in cardiac surgical patients . Anesth Analg. 82:1996;13-21.
3. Hardy J.-F., Desroches J. Natural and synthetic antifibrinolytics in cardiac surgery. Can J Anaesth. 39:1992;353-365.
4. Fremes S.E., Wong B.I., Lee E., et al. Metaanalysis of prophylactic drug treatment in the prevention of postoperative bleeding. Ann Thorac Surg. 58:1994;1580-1588.
5. Laupacis A., Fergusson D. Drugs to minimize perioperative blood loss in cardiac surgery meta-analyses using perioperative blood transfusion as the outcome . Anesth Analg. 85:1997;1258-1267.
6. Bidstrup B.P., Harrison J., Royston D., Taylor K.M., Treasure T. Aprotinin therapy in cardiac operations a report on use in 41 cardiac centers in the United Kingdom . Ann Thorac Surg. 55:1993;971-976.
7. Bidstrup B.P., Royston D., Sapsford R.N., Taylor K.M., Cosgrove D.M. Reduction in blood loss and blood use after cardiopulmonary bypass with high dose aprotinin. J Thorac Cardiovasc Surg. 97:1989;364-372.
8. Karski J.M., Teasdale S.J., Norman P., et al. Prevention of bleeding after cardiopulmonary bypass with high-dose tranexamic acid. Double-blind, randomized clinical trial. J Thorac Cardiovasc Surg. 110:1995;835-842.
9. Feindt P., Seyfert U.T., Volkmer I., Straub U., Gams E. Celite and kaolin produce differing activated clotting times during cardiopulmonary bypass under aprotinin therapy. Thorac Cardiovasc Surg. 42:1994;218-221.
10. Brown R.S., Thwaites B.K., Mongan P.D. Tranexamic acid is effective in decreasing postoperative bleeding and transfusions in primary coronary artery bypass operations a double-blind, randomized, placebo-controlled trial . Anesth Analg. 85:1997;963-970.
11. Westaby S. Aprotinin in perspective. Ann Thorac Surg. 55:1993;1033-1041.
12. Bennett-Guerrero E., Sorohan J.G., Gurevich M.L., et al. Cost-benefit and efficacy of aprotinin compared with ε-aminocaproic acid in patients having repeated cardiac operations. Anesthesiol. 87:1997;1373-1380.
13. Harmon D.E. Cost/benefit analysis of pharmacologic hemostasis. Ann Thorac Surg. 61:1996;S21-S25.
14. Tretiak R., Laupacis A., Rivière M., McKerracher K., Souêtre E. Cost of allogeneic and autologous blood transfusion in Canada. Can Med Assoc J. 154:1996;1501-1508.
15. Alderman E.L., Levy J.H., Rich J.B., et al. Analyses of coronary graft patency after aprotinin use results from the International Multicenter Aprotinin Graft Patency Experience (IMAGE) trial . J Thorac Cardiovasc Surg. 116:1998;716-730.
16. Karski J., Iwanochko M., Kucharczyk W., et al. Tranexamic acid and early graft patency in elective aortocoronary bypass (ACB) surgery. Can J Anesth. 5:1999;A29.
17. Westaby S., Katsumata T. Editorial aprotinin and vein graft occlusion - the controversy continues . J Thorac Cardiovasc Surg. 116:1998;731-733.
18. Bennett-Guerrero E., Sorohan J.G., Gurevich M.L., et al. Cost-benefit and efficacy of aprotinin compared with ε-aminocaproic acid in patients having repeated cardiac operations. Anesthesiol. 87:1997;1373-1380.
19. Blauhut B., Harringer W., Bettelheim P., Doran J.E., Späth P., Lundsgaard-Hansen P. Comparison of the effects of aprotinin and tranexamic acid on blood loss and related variables after cardiopulmonary bypass. J Thorac Cardiovasc Surg. 108:1994;1083-1091.
20. Boughenou F., Madi-Jebara S., Massonnet-Castel S., Benmosbah L., Carpentier A., Cousin M.T. Fibrinolytic inhibitors and prevention of bleeding in cardiac valve surgery. Comparison of tranexamic acid and high dose aprotinin. Arch Mal Coeur. 88:1995;363-370.
21. Corbeau J.J., Monrigal J.P., Jacob J.P., et al. Comparison of effects of aprotinin and tranexamic acid on blood loss in heart surgery. Ann Fr Anesth Réanim. 14:1995;154-161.
22. Cousin M.T., Boughenou F., Madi-Jebara S., Massonnet-Vastel S., Benmosbah L. The use of antifibrinolytics in heart surgery. 3 prospective studies. Cahiers d'Anesthésiologie. 41:1993;473-484.
23. Eberle B., Mayer E., Hafner G., et al. High-dose ε-aminocaproic acid versus aprotinin antifibrinolytic efficacy in first-time coronary operations . Ann Thorac Surg. 65:1998;667-673.
24. Jamieson W.R.E., Dryden P.J., O'Connor J.P., Sadeghi H., Ansley D.M., Merrick P.M. Beneficial effect of both tranexamic acid and aprotinin on blood loss reduction in reoperative valve replacement surgery. Circulation. 96:(Suppl II):1997;96-101.
25. Landymore R.W., Murphy T., Lummis H., Carter C. The use of low-dose aprotinin, ε-aminocaproic acid or tranexamic acid for prevention of mediastinal bleeding in patients receiving aspirin before coronary artery bypass operations. Eur J Cardiothorac Surg. 11:1997;798-800.
26. Menichetti A., Tritapepe L., Ruvolo G., et al. Changes in coagulation patterns, blood loss and blood use after cardiopulmonary bypass aprotinin vs tranexamic acid vs epsilon aminocaproic acid . J Cardiovasc Surg. 37:1996;401-407.
27. Mongan P.D., Brown R.S., Thwaites B.K. Tranexamic acid and aprotinin reduce postoperative bleeding and transfusions during primary coronary revascularization. Anesth Analg. 87:1998;258-265.
28. Penta de Peppo A., Pierri M.D., Scafuri A., et al. Intraoperative antifibrinolysis and blood-saving techniques in cardiac surgery. Prospective trial of 3 antifibrinolytic drugs. Tex Heart Inst J. 22:1995;231-236.
29. Pugh S.C., Wielogorski A.K. A comparison of the effects of tranexamic acid and low-dose aprotinin on blood loss and homologous blood usage in patients undergoing cardiac surgery. J Cardiothorac Vasc Anesth. 9:1995;240-244.
30. Speekenbrink R.G.H., Vonk A.B.A., Wildevuur C.R.H., Eijsman L. Hemostatic efficacy of dipyridamole, tranexamic acid, and aprotinin in coronary bypass grafting. Ann Thorac Surg. 59:1995;438-442.
31. Trinh-duc P., Wintrebert P., Boulfroy D., Albat B., Thevenet A., Roquefeuil B. Efficacy of ε-amino-caproic acid versus high-dose aprotinin on intra- and postoperative blood loss in cardiac surgery. Ann Chir Thorac Cardiovasc. 46:1992;677-683.